Cerus AI Stock Analysis
Want to see CERS full AI Analyst Report?
Cerus (CERS) AI Stock Analysis
Cerus
(NASDAQ:CERS)
The score is driven primarily by improving financial fundamentals (strong multi-year revenue growth, narrowing losses, and sharply reduced leverage), supported by a notably positive earnings call with reaffirmed 2026 guidance and strong clinical/regulatory progress (REDeS top-line results) plus sustained positive adjusted EBITDA. Offsetting this, technical momentum is soft (below key moving averages with slightly negative MACD), valuation is difficult to support with a negative P/E and no dividend, and free cash flow remains modest and less consistent.
Cerus (CERS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $400.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.93M
- Price to Earnings (P/E)
- -51.2
- Beta (1Y)
- 1.76
- Revenue Growth
- 13.74%
- EPS Growth
- 56.08%
- Country
- US
- Employees
- 268
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Cerus Business Overview & Revenue Model
Company Description
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, the...
How the Company Makes Money
Cerus makes money primarily by selling its INTERCEPT Blood System products and related consumables used in routine blood-component processing. Revenue is generated from (1) sales of single-use INTERCEPT processing kits/sets and associated reagents th...
Cerus Earnings Call Summary
The call was strongly positive overall. Cerus reported double-digit product revenue growth, reaffirmed full-year guidance, continued ISC and platelet adoption, stronger cash generation, positive adjusted EBITDA for the tenth consecutive quarter, and positive Phase III REDeS top-line results. The principal challenges were geopolitical and foreign-exchange headwinds in EMEA, a year-over-year gross-margin decline, declining government contract revenue, pending regulatory questions, and CE Mark timing now expected in late 2027. The number and significance of the stated achievements outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reaffirmed full year 2026 product revenue guidance of $229 million to $231 million, including full year 2026 IFC sales of $23 million to $25 million, and expects essentially all ISC sales will be in kit form in 2027. Cerus’ operating priorities include delivering sustainable double digit annual growth; it expects INT200 placements in EMEA to continue in the fourth quarter and some relief in Q4 from foreign exchange headwinds, expects CE Mark clearance in late 27 followed by a limited market release targeting centers of excellence in Europe, and considers the first half of 27 a reasonable expectation for the full REDeS data analysis, while providing no 2027 product revenue guidance.
Cerus Financial Statement Overview
Summary
Fundamentals are improving but not yet fully proven. Revenue has expanded materially (2021 $130.9M to 2025 $206.1M; $226.6M TTM) and losses have narrowed substantially (net margin from -41.6% in 2021 to -7.6% in 2025 and -3.2% TTM), with TTM EBITDA slightly positive. Balance sheet risk has improved meaningfully with debt down to ~$40.1M in TTM and debt/equity ~0.53x, but profitability is still not consistently positive (TTM EBIT and net income remain negative) and free cash flow is only modestly positive in TTM ($0.5M) and down sharply versus 2025 ($8.5M).
Income Statement
54NeutralBalance Sheet
62PositiveCash Flow
46Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 226.57M | 206.13M | 180.27M | 156.37M | 162.05M | 130.86M |
| Gross Profit | 117.44M | 112.29M | 99.52M | 86.40M | 87.09M | 67.38M |
| EBITDA | -5.16M | -5.51M | -10.02M | -26.34M | -33.52M | -45.99M |
| Net Income | -7.31M | -15.63M | -20.92M | -37.49M | -42.78M | -54.37M |
Balance Sheet | ||||||
| Total Assets | 204.73M | 221.86M | 200.92M | 197.75M | 218.09M | 237.50M |
| Cash, Cash Equivalents and Short-Term Investments | 57.11M | 82.88M | 80.45M | 65.85M | 102.15M | 129.36M |
| Total Debt | 74.96M | 96.95M | 98.10M | 96.00M | 87.24M | 87.59M |
| Total Liabilities | 128.37M | 156.89M | 144.02M | 144.30M | 149.53M | 151.88M |
| Stockholders Equity | 75.70M | 64.22M | 56.15M | 52.65M | 67.61M | 84.62M |
Cash Flow | ||||||
| Free Cash Flow | 494.00K | 8.52M | 8.52M | -47.77M | -27.61M | -34.83M |
| Operating Cash Flow | 3.50M | 11.36M | 11.36M | -43.17M | -25.61M | -33.92M |
| Investing Cash Flow | 17.94M | -8.13M | -8.13M | 8.62M | 8.46M | 12.69M |
| Financing Cash Flow | -21.10M | 4.96M | 4.96M | 10.67M | 4.19M | 34.29M |
Cerus Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Negative. The current price of 1.99 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.36, and below the 200-day MA of 2.43, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 38.64 is Neutral, neither overbought nor oversold. The STOCH value of 16.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CERS.
Cerus Risk Analysis
Cerus disclosed 39 risk factors in its most recent earnings report. Cerus reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCerus Peers Comparison
Overall Rating
BIO78Outperform
LIVN77Outperform
HAE71Outperform
CERS56Neutral
CTSO47Neutral
AEMD44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $9.86B | 9.60 | 14.07% | ― | 1.38% | ― | |
| 77Outperform | $5.03B | 25.51 | 15.35% | ― | 11.71% | ― | |
| 71Outperform | $5.60B | 54.16 | 12.07% | ― | 4.11% | -34.22% | |
| 56Neutral | $400.88M | -51.16 | -10.54% | ― | 13.74% | 56.08% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $15.35M | -0.91 | -1339.98% | ― | 9.04% | -43.07% | |
| 44Neutral | $8.49M | -0.50 | -141.22% | ― | ― | 90.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CERS | Cerus Corporation | 1.99 | 0.46 | 29.74% | |
| BIO | Bio-Rad Laboratories | 366.36 | 62.30 | 20.49% | |
| HAE | Haemonetics | 122.94 | 48.62 | 65.42% | |
| CTSO | Cytosorbents Corp | 4.87 | -8.25 | -62.89% | |
| LIVN | LivaNova PLC | 91.32 | 37.68 | 70.25% | |
| AEMD | Aethlon | 5.29 | -14.96 | -73.88% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
